Literature DB >> 36168086

The stem cell-specific long non-coding RNAs in leukemia.

Maryam Farzaneh1, Sajad Najafi2, Mohadeseh Sheykhi-Sabzehpoush3, Fereshteh Nezhad Dehbashi4, Omid Anbiyaee5, Ava Nasrolahi6, Shirin Azizidoost7.   

Abstract

Leukemia is defined as a heterogeneous group of hematological cancers whose prevalence is on the rise worldwide. Despite the large body of studies, the etiology of leukemia has not been fully elucidated. Leukemia stem cells (LSCs) are a subpopulation of cancer cells that sustain the growth of the leukemic clone and are the main culprit for the maintenance of the neoplasm. In contrast to most leukemia cells, LSCs are resistant to chemo- and radiotherapy. Several recent studies demonstrated the altered expression profile of long non-coding RNAs (lncRNAs) in LSCs and shed light on the role of lncRNAs in the survival, proliferation, and differentiation of LSCs. LncRNAs are transcripts longer than 200 nucleotides that are implicated in several cellular and molecular processes such as gene expression, apoptosis, and carcinogenesis. Likewise, lncRNAs have shown a prognostic marker in leukemia patients and represent novel treatment options. Herein, we review the current knowledge concerning lncRNAs' implication in the pathogenesis of LSCs and discuss their prognostic, diagnostic, and therapeutic potential.
© 2022. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).

Entities:  

Keywords:  Biomarker; Cancer; Leukemia; Long non-coding RNAs

Year:  2022        PMID: 36168086     DOI: 10.1007/s12094-022-02952-2

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.340


  35 in total

Review 1.  Molecular therapy for acute myeloid leukaemia.

Authors:  Catherine C Coombs; Martin S Tallman; Ross L Levine
Journal:  Nat Rev Clin Oncol       Date:  2015-12-01       Impact factor: 66.675

Review 2.  Diagnosis and treatment of therapy-related acute myeloid leukemia.

Authors:  Stephen A Strickland; Norbert Vey
Journal:  Crit Rev Oncol Hematol       Date:  2022-01-31       Impact factor: 6.312

Review 3.  Classification of acute myeloid leukemia.

Authors:  Sang Mee Hwang
Journal:  Blood Res       Date:  2020-07-31

Review 4.  Signaling pathways involved in chronic myeloid leukemia pathogenesis: The importance of targeting Musashi2-Numb signaling to eradicate leukemia stem cells.

Authors:  Foruzan Moradi; Sadegh Babashah; Majid Sadeghizadeh; Arsalan Jalili; Abbas Hajifathali; Hajifathali Roshandel
Journal:  Iran J Basic Med Sci       Date:  2019-06       Impact factor: 2.699

5.  An aging mouse model of human chronic myeloid leukemia.

Authors:  Taisen Hao; Chunxiao Zhang; Zhiqiang Wang; Alison Buck; Steven L Vonderfecht; Richard Ermel; Young Kim; WenYong Chen
Journal:  Oncogene       Date:  2021-04-06       Impact factor: 9.867

6.  In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.

Authors:  David I Marks; Laura Clifton-Hadley; Mhairi Copland; Jiaull Hussain; Tobias F Menne; Andrew McMillan; Anthony V Moorman; Nicholas Morley; Dina Okasha; Bela Patel; Pip Patrick; Michael N Potter; Clare J Rowntree; Amy A Kirkwood; Adele K Fielding
Journal:  Lancet Haematol       Date:  2022-04       Impact factor: 18.959

Review 7.  Chronic myeloid leukemia stem cells: targeting therapeutic implications.

Authors:  Hanieh Mojtahedi; Niloufar Yazdanpanah; Nima Rezaei
Journal:  Stem Cell Res Ther       Date:  2021-12-18       Impact factor: 6.832

Review 8.  Etiology of Acute Leukemia: A Review.

Authors:  Cameron K Tebbi
Journal:  Cancers (Basel)       Date:  2021-05-08       Impact factor: 6.639

Review 9.  Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.

Authors:  Lia Walcher; Ann-Kathrin Kistenmacher; Huizhen Suo; Reni Kitte; Sarah Dluczek; Alexander Strauß; André-René Blaudszun; Tetyana Yevsa; Stephan Fricke; Uta Kossatz-Boehlert
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.